Biomarkers are Fast Gaining Importance Fueled by Innovations in Transcriptomics, Proteomics and Metabolomics - RI Technologies Provides an Informative Market Insight

Share Article

Global Biomarkers market is projected to grow at 21.8% compounded annually from 2005 through 2015, driven mainly by integration of biomarkers into clinical trials. Biomarkers are expected to increase productivity by identifying potential drug failures in initial stages, leading to savings in time and costs. Biomarkers are becoming an essential part of drug discovery process, bolstering efficiency and accuracy. Biomarkers identification is fast gaining importance, especially in the field of medical research. Latest innovations in the area of transcriptomics, proteomics and metabolomics are driving the trend. Despite Systems Biology providing a better description and understanding of disease pathologies, biomarker identification continues to face challenges. Development of innovative technologies by small and mid-sized companies is prompting major pharma companies to form strategic alliances to identify biomarkers. Current investments in biomarker research and development efforts by pharmaceutical companies would help in discovering a new drug or combinations of biomarker tests. An enormous market opportunity is expected for biomarkers in the near future, as personalized medicine becomes a reality making conventional approaches obsolete.

The need for accurate and precise molecular diagnostics to characterize the human disease state to deliver the appropriate and most effective therapies is triggering the field to develop more and more novel biomarkers of disease. Huge investments are being made by leading companies in biomarker identification process owing to the enormous scope they foresee in this field and other related fields such as oncology. The number of companies investing in the biomarker identification field has enormously increased in the last decade. Research statistics quote that investments in the field of biomarkers have increased by a mammoth rate of over 200%. This growth rate is expected to further rise as there is huge pressure on the pharmaceutical industry to discover new drugs to meet medical requirements. The main target area of investment is in the field of Oncology that accounts for more than 30% of the total investments in the biomarker identification field, closely followed by cardiology and neurology accounting for 50% share.

Gene expression biomarkers are of current interest as a tool for developing longevity-enhancing drugs. Following the completion of the human genome project, intense research is underway to identify various proteins and genes instrumental in causing a diseased state. Detection of cancer offers great scope for implementation of genomic biomarkers, as it is a disease concerned with the genes.

In the field of drug development biomarkers are primarily used for clinical and preclinical studies and patient diagnostics. Biomarkers are used for in vitro and in vivo studies for diagnosing disease causes and progressions. In the process of clinical trials the use of biomarker provides important information about patient selection, diagnosis and therapeutic results. In clinical applications, biomarkers help in establishing customized therapies. The pharmaceutical industry aims to tap into the potential offered by genomic technologies.

The complexity and the wide dynamic range in protein concentrations of human plasma makes it difficult to characterize a potential biomarker candidate. Major imaging technologies that can be used for biomarker identification include Computer Tomography (CT) scanning, Magnetic Resonance Imaging (MRI) scanning, Ultrasound or Sonography using MRI, Positron Emission Tomography (PET), Magnetic Resonance Angiography (MRA) and Magnetic Resonance Spectroscopy (MRS).

RI Technologies’ (http://www.researchimpact.com) report on Biomarkers focuses on the different types of biomarkers and their impact on various disease areas such as oncology (prostate, ovarian, breast and lung), neurology (stroke, brain tumor, neurodegenerative diseases), cardiology (coronary heart disease, heart failure, myocardial infarction), infectious diseases (GIT, respiratory tract infections) and other areas including metabolomic turmoil, arthritis, gynecology, oxidative stress, liver disease, pulmonary disease and aging, etc. The study provides global market analysis for biomarkers by the above disease areas and also by prominent biomarker identification technologies including imaging, genomics, proteomics, metabolomics, gene expression and other technologies comprising fluorescent indicators, lab-on-chip, nuclear magnetic resonance, mass spectrometry/liquid chromatography and nanobiotechnology. Compilation of Worldwide Patents and Research related to Biomarkers is also provided. The report offers market values for global geographic regions including United States, Europe, Japan, Asia-Pacific, Canada and Rest of World.

For more information, please visit - http://www.researchimpact.com/MIR003_BIOMARKERS.aspx.
Customer Support: contactus (at) researchimpact (dot) com
Phone: India: +91 9676994272 / UK: 076-24-057837

About RI Technologies
RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector with exclusive focus on product segments, global and regional market analysis, technology trends, industry outlook, competitor profiles, corporate directory and patents information. The company believes in pure research that will trigger action for immediate customer needs rather than plain reporting of data. The dedicated team works 24/7 to deliver unique reports that are of immense value to investment banks, companies, management consultants, trade associations, corporate executives, business analysts, libraries, universities, and business schools. The company's reports provide strategic information tools to manufacturers, retailers, distributors, and suppliers that will help them to probe into and support critical business decisions. RI Technologies believes in broadening the value of market research obtained through several dedicated streams of information. The strategic market information tables, graphically represented, will aid companies' research needs and help in forecasting, and gearing up to the future. Emphasis is on factual insights and forecasts with maximum global coverage. The company strives to provide market insight reports that empower customers with enlightening critical business information.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

contactus
Visit website